Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Intellia Therapeutics Stock Performance
Shares of NASDAQ:NTLA opened at $17.99 on Friday. Intellia Therapeutics, Inc. has a 52 week low of $17.43 and a 52 week high of $34.87. The company has a market cap of $1.74 billion, a PE ratio of -3.36 and a beta of 1.76. The firm has a 50 day simple moving average of $22.00 and a 200 day simple moving average of $23.51.
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. The firm’s revenue was down 48.5% on a year-over-year basis. During the same period in the previous year, the business earned ($1.40) EPS. On average, equities analysts predict that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current year.
Institutional Trading of Intellia Therapeutics
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on NTLA. Royal Bank of Canada reiterated an “outperform” rating and issued a $54.00 price target on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. JPMorgan Chase & Co. reduced their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.77.
View Our Latest Stock Analysis on NTLA
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Read More
- Five stocks we like better than Intellia Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- 3 Stocks to Consider Buying in October
- MarketBeat Week in Review – 9/30 – 10/4
- How to Calculate Options Profits
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.